Please login to the form below

Not currently logged in
Email:
Password:

Promising Innovative Medicine

This page shows the latest Promising Innovative Medicine news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Airbus relocation woes, inflated taxes will pay for NHS boost, NICE OK's Sanofi's Dupixent and more

Daily Brief: Airbus relocation woes, inflated taxes will pay for NHS boost, NICE OK's Sanofi's Dupixent and more

The drug gained a Promising Innovative Medicine designation from the UK’s regulator the MHRA, an early access scheme which operated before it gained EU marketing approval.

Latest news

  • Pfizer’s first-in-class breast cancer therapy wins EU licence Pfizer’s first-in-class breast cancer therapy wins EU licence

    The European Commission has granted Pfizer's first-line breast cancer drug Ibrance marketing authorisation in Europe, making it the first new medicine to get to market in this setting in ... The first-in-class treatment was awarded Promising Innovative

  • NICE 'no' for Opdivo in kidney cancer NICE 'no' for Opdivo in kidney cancer

    Johanna Mercier, general manager, Bristol-Myers Squibb UK &Ireland, said: “ Nivolumab is a game-changing medicine, which has been consistently recognised, in its approved indications, by the Medicines and Healthcare products ... Regulatory Agency (MHRA)

  • Novartis still hungry after absorbing GSK oncology Novartis still hungry after absorbing GSK oncology

    Jimenez is however already in the market for mid-scale acquisitions in the $2bn-$5bn range to bolster its three core units in innovative pharma, eyecare and generics. ... Early access for LCZ696. The Swiss drug major is celebrating another positive

  • Novartis cancer pill makes it onto UK early access list Novartis cancer pill makes it onto UK early access list

    The UK drugs regulator the MHRA has granted a 'promising innovative medicine' for its new lung cancer drug Zykadia (ceritinib). ... Specifically, the pill has been designated as a promising innovative medicine (PIM) for the treatment of patients with

  • Keytruda is UK's first early-access medicine Keytruda is UK's first early-access medicine

    Keytruda is UK's first early-access medicine. Merck’ s melanoma therapy accepted under the UK’ s EAMS. ... In January, BMS claimed Opdivo was the first PD-1 inhibitor to be awarded Promising Innovative Medicine (PIM) status - the first stage in the

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis. ... Along the way it also received a

  • Creating a 21st century life sciences ecosystem Creating a 21st century life sciences ecosystem

    Part of the scheme involves a new 'promising innovative medicine' designation - similar to the FDA's breakthrough designation - the first of which have started to be awarded. ... Date Issued. Promising Innovative Medicine Designations. Details. September

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics